基本信息
浏览量:5
职业迁徙
个人简介
Research focus of my laboratory is to identify treatment strategies and underlying mechanism of therapy-resistant cancers by studying phenotypic and genotypic tumor characteristics. I am most intrigued by the heterogeneous response of cancers to a wide range of therapies. By using mitochondrial priming as a platform, we have found that early changes in mitochondrial signaling can assign individualized in-vivo therapy for acute myeloid leukemia PDX models and patient tumors.
The primary goals of my laboratory are (i) to measure mitochondrial apoptosis signaling using BH3 profiling to accurately predict response to targeted therapy in blood cancer (ii) to understand why some leukemia cells persist during therapy (iii) to determine how to combine functional and genomic approaches to guide precision target identification in a relapsed cancers (iv) to study clonal architecture of leukemia relapse. To investigate these problems, we are doing functional measurements to determine how chemical vulnerabilities evolve during leukemia treatment and whether drug sensitivities in a relapsed disease can be linked to genetic abnormalities. We are performing multi-dimensional studies involving mitochondrial outer membrane potential measurements, targeted exome sequencing, transcriptomics and DNA barcoding. We are exploiting human blood cancer cell lines, patient-derived xenograft models and primary tumor specimens to address our hypothesis.
The primary goals of my laboratory are (i) to measure mitochondrial apoptosis signaling using BH3 profiling to accurately predict response to targeted therapy in blood cancer (ii) to understand why some leukemia cells persist during therapy (iii) to determine how to combine functional and genomic approaches to guide precision target identification in a relapsed cancers (iv) to study clonal architecture of leukemia relapse. To investigate these problems, we are doing functional measurements to determine how chemical vulnerabilities evolve during leukemia treatment and whether drug sensitivities in a relapsed disease can be linked to genetic abnormalities. We are performing multi-dimensional studies involving mitochondrial outer membrane potential measurements, targeted exome sequencing, transcriptomics and DNA barcoding. We are exploiting human blood cancer cell lines, patient-derived xenograft models and primary tumor specimens to address our hypothesis.
研究兴趣
论文共 53 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
FRONTIERS IN ONCOLOGY (2024): 1275251-1275251
Aarthi Nivasini Mahesh,Joanne Lai XIN-Yi, Mei-Chun Lin,Weilin Lin, Jia Wan,Jung‐Hwan Yoon,Kaiwen Chen,Shruti Bhatt
bioRxiv (Cold Spring Harbor Laboratory) (2023)
引用0浏览0引用
0
0
Aarthi Nivasini Mahesh,Joanne Lai XIN-Yi, Mandy Tng Jia Lin,Weilin Lin, Jia Cheng Wan,Junho Yoon,Kaiwen Chen,Shruti Bhatt
biorxiv(2023)
引用0浏览0引用
0
0
Leukemiano. 6 (2022): 1700-1700
Clinical Lymphoma, Myeloma & Leukemia (2021): S87-S88
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn